Celcuity Inc. (CELC)

$7.55

-0.50 (-6.21%)
Rating:
Recommendation:
Neutral
Symbol CELC
Price $7.55
Beta 1.002
Volume Avg. 0.03M
Market Cap 116.721M
Shares () -
52 Week Range 4.81-14.78
1y Target Est -
DCF Unlevered CELC DCF ->
DCF Levered CELC LDCF ->
ROE -62.64% Strong Sell
ROA -54.44% Strong Sell
Operating Margin -
Debt / Equity 50.01% Buy
P/E -3.12 Strong Sell
P/B 2.59 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CELC news


Mr. Brian F. Sullivan
Healthcare
Biotechnology
NASDAQ Capital Market

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.